Outsourced Pharma Webinars

  1. Challenges And Opportunities In The Development Of Biologic Drugs
    7/20/2017

    With transformational changes in biologics, there are increasingly newer formats of new biologic drugs including bispecific antibodies, antibody drug conjugates and antibody-peptide fusion proteins.

  2. Optimize Biologic Drug Development With The Power Of Scientific Informatics
    7/20/2017

    The complex structure of Biologics, the nature of the interactions with their partners, require accurate modelling method to predict their physicochemical properties.

  3. Visibility and Oversight: What Paper Informed Consent Isn’t Offering You (Featuring Guest Speaker, Chesapeake IRB)
    3/8/2017

    Chesapeake IRB and CRF Health team up for a collaborative webinar to discuss informed consent oversight and visibility and why Top Pharma is turning to Electronic Informed Consent (eConsent) to exceed in these areas.

  4. The World’s Best eCOA Body Map: How Patients Improved Symptom Location Reporting
    3/7/2017

    The burden of ineffective and inefficient body maps creates risks that can impact data quality. We knew we could come up with something much better - for all stakeholders.

  5. An Alternative To Achieve Speed And Scalability To Microbial Expression For Next-Gen Therapeutics
    2/17/2017

    The newly developed G1-3 fermentation process makes use of short, straightforward fermentation regimes for optimized space time yield.

  6. Integrating Safety And Immunogenicity Assessments Into The Biopharma Preclinical Development Process
    9/27/2016

    Efficacy, safety, immunogenicity and manufacturability issues play a large role in the high attrition rate of biopharmaceutical candidates each year. To help reduce the risk of failure, tools to address the developability of preclinical candidates have been established.

  7. Innovations In E-Consent: Reducing Regulatory Risk While Improving Participant Comprehension
    6/16/2016

    Informed consent has a major impact on regulatory compliance, enrollment rates and expenses across the life of your study. Yet the traditional paper-based process has transformed informed consent into one of the most cited deficiencies.

  8. Expression Of Next Generation Biologics Requires Next Generation Expression Systems
    6/2/2016

    Next generation biologics include, but are not limited to, novel antibody formats or antibody derived molecules that are translating into promising next generation therapeutics.  Such highly diverse molecule formats demand a range of expression platforms in order to optimize production yields and quality. To address the complexity of these novel compounds, Lonza offers both mammalian and microbial expression platforms.

  9. eCOA Essentials: 1 Hour To Higher Quality Data
    5/5/2016

    The industry's shift from paper to electronic Clinical Outcome Assessments (eCOA) in clinical trials is happening at dizzying speeds.

  10. eCOA And Equivalence Testing: New Evidence From Meta-Analysis
    2/1/2016

    The evaluation of the compatibility between scores from an electronic version of a paper-based questionnaire, better known as equivalence testing, is usually taken as a requirement for ensuring that data from electronic versions of patient reported outcomes does not vary from that captured on paper. This webinar discusses the results of a recently published meta-analysis which examined all published equivalence tests from 2007 to 2013. This webinar discusses equivalence testing, how the current meta-analysis run, and what the results mean in context of the field of eCOA.